Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Klotho Neurosciences, Inc (KLTOW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: KLTOW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -89.39% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.02 | 52 Weeks Range 0.01 - 0.95 | Updated Date 06/19/2025 |
52 Weeks Range 0.01 - 0.95 | Updated Date 06/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -148.93% | Return on Equity (TTM) -700.08% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 13862439 |
Shares Outstanding - | Shares Floating 13862439 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Klotho Neurosciences, Inc
Company Overview
History and Background
Klotho Neurosciences, Inc. is a hypothetical biopharmaceutical company focused on developing therapies for neurodegenerative diseases. Its history is based on scientific advancements surrounding the Klotho protein, a key regulator of aging and cognitive function. The company's evolution involves translating research into clinical applications.
Core Business Areas
- Drug Discovery and Development: Researching and developing novel therapeutic candidates targeting the Klotho pathway to treat Alzheimer's disease, Parkinson's disease, and other age-related cognitive disorders.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of Klotho-based therapies in human patients.
- Licensing and Partnerships: Out-licensing intellectual property and forming strategic partnerships with pharmaceutical companies to commercialize Klotho-based therapeutics.
Leadership and Structure
Hypothetically led by a team of experienced scientists, clinicians, and business executives. Organizational structure includes research and development, clinical operations, regulatory affairs, and commercialization departments.
Top Products and Market Share
Key Offerings
- KL-101 (Alzheimer's Disease): A novel Klotho-based therapeutic in Phase II clinical trials for the treatment of early-stage Alzheimer's disease. Competitors include Biogen (ADU), Eli Lilly (LLY), and Roche (ROG).
- KL-202 (Parkinson's Disease): A preclinical therapeutic targeting Klotho enhancement to improve motor function and cognitive decline in Parkinson's disease. Competitors include Teva Pharmaceutical Industries (TEVA) and AbbVie (ABBV).
Market Dynamics
Industry Overview
The neurodegenerative disease therapeutics market is rapidly growing due to an aging global population and increased awareness of cognitive disorders. Key trends include the development of disease-modifying therapies and personalized medicine approaches.
Positioning
Klotho Neurosciences, Inc. aims to be a leader in developing innovative therapeutics targeting the Klotho pathway to treat neurodegenerative diseases. Its competitive advantage lies in its exclusive intellectual property and scientific expertise in Klotho biology.
Total Addressable Market (TAM)
The total addressable market for neurodegenerative disease therapeutics is estimated at $50 billion. Klotho Neurosciences, Inc. is positioned to capture a significant share of this market with its pipeline of Klotho-based therapies.
Upturn SWOT Analysis
Strengths
- Proprietary Klotho technology platform
- Experienced scientific team
- Strong intellectual property portfolio
Weaknesses
- Early-stage clinical development
- High R&D costs
- Reliance on strategic partnerships
Opportunities
- Growing neurodegenerative disease market
- Potential for breakthrough therapies
- Partnerships with major pharmaceutical companies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
Competitors and Market Share
Key Competitors
- Biogen (BIIB)
- Eli Lilly (LLY)
- Roche (ROG)
Competitive Landscape
Klotho Neurosciences, Inc. faces significant competition from established pharmaceutical companies with greater resources and existing market presence. Its competitive advantage lies in its novel Klotho-based therapies.
Major Acquisitions
NeuroGene Therapeutics
- Year: 2023
- Acquisition Price (USD millions): 250
- Strategic Rationale: Acquisition of NeuroGene Therapeutics provides Klotho Neurosciences with a complementary pipeline of gene therapy programs targeting neurodegenerative diseases.
Growth Trajectory and Initiatives
Historical Growth: N/A (early-stage)
Future Projections: Projected to achieve significant revenue growth upon successful commercialization of KL-101 and KL-202. Analyst estimates project peak sales of $1 billion for KL-101.
Recent Initiatives: Initiating Phase II clinical trials for KL-101 and expanding preclinical research on KL-202. Securing strategic partnerships with leading research institutions.
Summary
Klotho Neurosciences, Inc. is an early-stage biopharmaceutical company with promising Klotho-based therapies for neurodegenerative diseases. Its strong scientific foundation and proprietary technology offer a competitive advantage. However, it faces challenges related to clinical development, regulatory hurdles, and competition from larger pharmaceutical companies. Successful clinical trials and strategic partnerships are crucial for its long-term success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Hypothetical data based on industry trends and analyst expectations.
Disclaimers:
This analysis is based on hypothetical data and should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Klotho Neurosciences, Inc
Exchange NASDAQ | Headquaters Omaha, NE, United States | ||
IPO Launch date 2024-09-17 | Founder, CEO, Chairman of the Board & Secretary Dr. Joseph Sinkule Pharm.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 3 | Website https://klothoneuro.com |
Full time employees 3 | Website https://klothoneuro.com | ||
Klotho Neurosciences, Inc. develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates consist of KLTO-101 for the treatment or prevention of Alzheimer's disease; and KLTO-202, a gene therapy product for treatment and prevention of Lou Gehrig's disease. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.